CJC-1295 + Ipamorelin Blend (GHRH + GHRP Research Blend) — Certificate of Analysis

Lot CP10-2026-001 of CJC-1295 + Ipamorelin Blend assayed at 99.77% peptide purity by RP-HPLC against a ≥95.0% release specification, 4.77 percentage points clear of it. Released 07/17/2026 by ILS Laboratories, ISO/IEC 17025 Accredited. Co-lyophilized research blend pairing the GHRH analog CJC-1295 (no DAC) with the selective GHRP pentapeptide Ipamorelin.

Full QC panel

Analyte	Specification	Result	Status
Peptide Purity (HPLC)	≥ 95.0%	99.77%	Pass
Fentanyl Screen	Immunoassay, 50 ng/mL cutoff	Not Detected	Pass

Sterility & endotoxin

Test	Specification	Result	Status
Sterility (PCR)	No Growth	No Growth	Pass
Endotoxin (USP <85>)	Report Result	NMT 0.05 EU/mL	Reported

Endotoxin is reported as a measured value rather than graded pass/fail: acceptable limits depend on route and matrix, and no universal threshold applies to research-use material. The laboratory reports the figure and leaves the judgement to you.

Elemental impurities

Panel	Method	Result	Status
Arsenic, cadmium, chromium, lead, mercury	ICP-MS, USP <233>	5 of 5 under limit	Pass

Per-element measurements are on the signed certificate below and in the laboratory's own record.

Reference data

Property	Value
Compound	CJC-1295 + Ipamorelin Blend (GHRH + GHRP Research Blend)
Also known as	CJC-1295 (no DAC) / Ipamorelin, Mod GRF (1-29) + Ipamorelin, GHRH/GHRP research blend, CJC-1295 DAC-free + Ipamorelin stack
Physical form	Lyophilized powder (co-lyophilized blend)
Storage	Store lyophilized powder at -20 C protected from light and moisture; stable for extended periods when sealed. After reconstitution, store at 2-8 C and use within research-validated stability windows; aliquot to minimize freeze-thaw cycles.